Article
Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia.
Clinical pharmacology and therapeutics - 1 Dec 2014
Davies A, Giannoudis A, Zhang J E, Austin G, Wang L, Holyoake T L, Müller M C, Foroni L, Kottaridis P D, Pirmohamed M, Clark R E
Abstract excerpt
Approximately 40% of patients with chronic myeloid leukemia (CML) receiving imatinib fail treatment. There is an increased risk of CML in subjects with (i) deletions of genes encoding glutathione-S-transferase (GST)-θ1 (GSTT1) and -μ1, (GSTM1) and (ii) the GST-π1 (GSTP1) single-nucleotide polymorphism (SNP) Ile105Val (GSTP1*B; rs1695); however, their effects on imatinib treatment outcome are not known. Here, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.